会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Heterocyclic compounds and pharmaceutical use
    • 杂环化合物和药物用途
    • US4250173A
    • 1981-02-10
    • US094100
    • 1979-11-14
    • Barrie C. C. Cantello
    • Barrie C. C. Cantello
    • C07D263/28C07D265/08C07D277/18C07D279/06A61K31/425A61K31/535A61K31/54
    • C07D265/08C07D263/28C07D277/18C07D279/06
    • A compound, with hypolgycaemic activity, having formula (II) or a pharmaceutically acceptable quaternary ammonium or acid addition salt thereof: ##STR1## wherein X represents oxygen or sulphur; n.sub.7 represents zero or 1;R.sup.7 represents hydrogen or C.sub.1-6 alkyl;R.sup.1 and R.sup.2 are the same or different and represent hydrogen, C.sub.1-6 alkyl, phenyl, benzyl, or C.sub.3-6 cycloalkyl;R.sup.3 represents hydrogen, C.sub.1-6 alkyl, phenyl or benzyl;R.sup.4 represents hydrogen or C.sub.1-6 alkyl;R.sup.5 represents C.sub.1-6 alkyl, phenyl optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl, and C.sub.1-6 alkoxy; or benzyl optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl and C.sub.1-6 alkoxy; or R.sup.4 and R.sup.5 together represent the remaining members of a 5- or 6-membered ring optionally containing an oxygen, sulphur or additional nitrogen atom and being optionally substituted with C.sub.1-6 alkyl, carboxy or C.sub.1-6 alkoxycarbonyl; andR.sup.6 represents phenyl, optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkanoyl, C.sub.1-6 alkanoyloxy, nitro, hydroxy, amino, substituted amino, carboxy, and C.sub.1-6 alkoxycarbonyl.
    • 具有降血糖活性的化合物,具有式(II)或其药学上可接受的季铵或其酸加成盐:其中X表示氧或硫; n7表示零或1; R 7表示氢或C 1-6烷基; R 1和R 2相同或不同,表示氢,C 1-6烷基,苯基,苄基或C 3-6环烷基; R3代表氢,C1-6烷基,苯基或苄基; R4表示氢或C1-6烷基; R5表示C1-6烷基,任选被至多3个选自卤素,C 1-6烷基和C 1-6烷氧基的基团取代的苯基; 或任选被至多3个选自卤素,C 1-6烷基和C 1-6烷氧基的基团取代的苄基; 或R 4和R 5一起代表任选地含有氧,硫或另外的氮原子并任选被C 1-6烷基,羧基或C 1-6烷氧基羰基取代的5-或6-元环的剩余成员; 并且R 6表示任选被至多3个选自卤素,C 1-6烷基,C 1-6烷氧基,C 1-6烷酰基,C 1-6烷酰氧基,硝基,羟基,氨基,取代的氨基,羧基和C1- 6烷氧基羰基。
    • 4. 发明授权
    • Method of treating diabetes using oxazoline or thiazoline compounds
    • 使用恶唑啉或噻唑啉化合物治疗糖尿病的方法
    • US4409216A
    • 1983-10-11
    • US139284
    • 1980-04-11
    • Barrie C. C. Cantello
    • Barrie C. C. Cantello
    • C07D277/20A61K31/42A61K31/421A61P3/08A61P3/10C07D263/48C07D277/48C07D277/82A61K31/425A61K31/535A61K31/54
    • C07D263/48C07D277/48C07D277/82
    • A compound, with hypoglycaemic activity, having formula (II) or a pharmaceutically acceptable acid addition salt thereof: ##STR1## wherein X represents oxygen or sulphur;R.sup.1 R.sup.2 are the same or different and represent hydrogen, halogen, C.sub.1-6 alkyl, phenyl, benzyl,C.sub.3-6 cycloalkyl, carbo-C.sub.1-6 alkoxy or C.sub.1-6 carboxy or R.sup.1 and R.sup.2 represent the remaining members of a benzene ring;R.sup.3 represents hydrogen, C.sub.1-6 alkyl, phenyl or benzyl;R.sup.4 represents hydrogen or C.sub.1-6 alkyl;R.sup.5 represents C.sub.1-6 alkyl, phenyl optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl, and C.sub.1-6 alkoxy; or benzyl optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl and C.sub.1-6 alkoxy; or R.sup.4 and R.sup.5 together represent the remaining members of a 5- or 6- membered ring optionally containing an oxygen, sulphur or additional nitrogen atom and being optionally substituted with C.sub.1-6 alkyl; andR.sup.6 represents C.sub.1-6 alkyl, phenyl, optionally substituted with up to 3 groups selected from halogen, nitro-, amino-, trifluoromethyl, C.sub.1-6 alkyl and C.sub.1-6 alkoxy; or benzyl optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl and C.sub.1-6 al
    • 具有低血糖活性的化合物,具有式(II)或其药学上可接受的酸加成盐:其中X表示氧或硫; R1 R2相同或不同,代表氢,卤素,C 1-6烷基,苯基,苄基,C 3-6环烷基,碳-C 1-6烷氧基或C 1-6羧基或R 1和R 2表示苯环的剩余成员 ; R3代表氢,C1-6烷基,苯基或苄基; R4表示氢或C1-6烷基; R5表示C1-6烷基,任选被至多3个选自卤素,C 1-6烷基和C 1-6烷氧基的基团取代的苯基; 或任选被至多3个选自卤素,C 1-6烷基和C 1-6烷氧基的基团取代的苄基; 或R 4和R 5一起代表5-或6-元环的任选含有氧,硫或另外的氮原子并且任选地被C 1-6烷基取代的剩余成员; R 6表示C 1-6烷基,苯基,任选被至多3个选自卤素,硝基,氨基 - ,三氟甲基,C 1-6烷基和C 1-6烷氧基的基团取代; 或任选被至多3个选自卤素,C 1-6烷基和C 1-6的基团取代的苄基
    • 5. 发明授权
    • Secondary amines and use in pharmaceutical compositions
    • 仲胺并用于药物组合物
    • US4629737A
    • 1986-12-16
    • US513869
    • 1983-07-14
    • Barrie C. C. Cantello
    • Barrie C. C. Cantello
    • A61K31/135A61K31/19C07C43/225C07C43/303C07C43/313C07C229/38C07D307/81C07C101/16A61K31/195A61K31/215C07C101/447
    • C07C255/00C07C229/38C07C43/225C07C43/303C07C43/313C07D307/81
    • A compound of formula (I): ##STR1## or a pharmaceutically acceptable salt, ester or amide thereof, in which: W is an optionally substituted phenyl group of the formula ##STR2## wherein R.sup.1 is hydrogen or fluorine, R.sup.2 is hydrogen, C.sub.1-6 alkyl, halogen or trifluoromethyl; or W is a phenoxymethyl or benzofuran-2-yl group;R.sup.3 is C.sub.1-12 alkyl or phenyl C.sub.1-6 alkyl;A is hydrogen or methyl,X is carboxy, --Z--CO.sub.2 H, --Z--OH, T--Z--CO.sub.2 H,--Z--NR.sup.4 R.sup.5, --T--Y--OM, --T--Y--NR.sup.4 R.sup.5, or --T--R.sup.6, in the para- or meta-position with respect to the --(CH.sub.2).sub.n group, whereinR.sup.4 and R.sup.5 are each hydrogen or C.sub.1-6 alkyl,R.sup.6 is C.sub.1-6 alkyl,T is 0, S, --NH or --N--R.sup.7, in which R.sup.7 is C.sub.1-6 alkylZ is C.sub.1-10 straight or branched alkylene optionally containing a carbon-carbon double bond;Y is C.sub.2-10 straight or branched alkylene, provided that the hetero atoms in --T--Y--OM and --T--Y--NR.sup.4 R.sup.5 are separated by at least two carbon atoms, M is hydrogen, C.sub.1-6 alkyl or phenyl, and n is 1 or 2, is useful for obesity or hyperglycaemia.
    • 式(I)的化合物:其中:W是任选取代的下式的苯基,其中R 1是氢或氟,R 2是 氢,C 1-6烷基,卤素或三氟甲基; 或W是苯氧基甲基或苯并呋喃-2-基; R3是C1-12烷基或苯基C1-6烷基; A是氢或甲基,X是羧基,-Z-CO 2 H,-Z-OH,TZ-CO 2 H,-Z-NR 4 R 5,-TY-OM,-TY-NR 4 R 5或-T- 相对于 - (CH 2)n基的间位,其中R 4和R 5各自为氢或C 1-6烷基,R 6为C 1-6烷基,T为0,S,-NH或-N-R 7,其中 R 7是C 1-6烷基Z是任选含有碳 - 碳双键的C 1-10直链或支链亚烷基; Y是C2-10直链或支链亚烷基,条件是-TY-OM和-TY-NR4R5中的杂原子被至少两个碳原子分开,M是氢,C 1-6烷基或苯基,n是1或 2,可用于肥胖或高血糖。
    • 9. 发明授权
    • Carboxamidine derivatives and hypoglycemical use
    • 卡巴胺衍生物和低血糖用途
    • US4333929A
    • 1982-06-08
    • US226180
    • 1981-01-19
    • Barrie C. C. Cantello
    • Barrie C. C. Cantello
    • A61K31/155A61P3/08A61P3/10C07C67/00C07C239/00C07C279/26C07C281/16C07D295/215A61K31/54C07C129/00C07D279/10
    • C07D295/215C07C279/26Y10S514/866
    • A compound of formula (II) or a pharmaceutically acceptable acid addition salt thereof ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are the same or different and each represents C.sub.1-6 alkyl; R.sup.5 represents hydrogen or C.sub.1-6 alkyl; R.sup.6 represents C.sub.1-6 alkyl, phenyl optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl, and C.sub.1-6 alkoxy; or benzyl optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl and C.sub.1-6 alkoxy; or R.sup.5 and R.sup.6 together represent the remaining members of a 5- or 6-membered ring optionally containing an oxygen, sulphur or additional nitrogen atom and being optionally substituted with C.sub.1-6 alkyl, carboxy or C.sub.1-6 alkoxycarbonyl; and R.sup.7 represents C.sub.1-6 alkyl, phenyl optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl and C.sub.1-6 alkoxy; or benzyl optionally substituted with up to 3 groups selected from halogen, C.sub.1-6 alkyl and C.sub.1-6 alkoxy, has useful hypoglycaemic activity.
    • 式(II)化合物或其药学上可接受的酸加成盐其中R 1,R 2,R 3和R 4相同或不同,各自表示C 1-6烷基; R5表示氢或C1-6烷基; R 6表示C 1-6烷基,任选被至多3个选自卤素,C 1-6烷基和C 1-6烷氧基的基团取代的苯基; 或任选被至多3个选自卤素,C 1-6烷基和C 1-6烷氧基的基团取代的苄基; 或R 5和R 6一起表示任选地含有氧,硫或另外的氮原子并且任选被C 1-6烷基,羧基或C 1-6烷氧基羰基取代的5-或6-元环的剩余成员; 并且R 7表示C 1-6烷基,任选被至多3个选自卤素,C 1-6烷基和C 1-6烷氧基的基团取代的苯基; 或任选被至多3个选自卤素,C 1-6烷基和C 1-6烷氧基的基团取代的苄基具有有效的低血糖活性。